2024
Influence of lamina propria invasion extension on T1 high‐grade non‐muscle‐invasive bladder cancer in patients undergoing BCG or radical cystectomy
Contieri R, Tan W, Grajales V, Hensley P, Martini A, Bree K, Myers A, Nogueras‐Gonzalez G, Navai N, Dinney C, Guo C, Kamat A. Influence of lamina propria invasion extension on T1 high‐grade non‐muscle‐invasive bladder cancer in patients undergoing BCG or radical cystectomy. BJU International 2024, 133: 733-741. PMID: 38374533, DOI: 10.1111/bju.16293.Peer-Reviewed Original ResearchConceptsNon-muscle-invasive bladder cancerImmediate radical cystectomyCancer-specific survivalMetastasis-free survivalProgression-free survivalT1 substagingOverall survivalRadical cystectomyPathology reportsBladder cancerHigh-grade non-muscle-invasive bladder cancerPatients treated with bacillus Calmette-GuerinAssociated with poor progression-free survivalInstitutional review board-approved retrospective studyPatients treated with BCGPoor progression-free survivalLamina propriaAssociated with upstagingBCG-treated patientsCalculate overall survivalTreated with BCGKaplan-Meier methodHigh-grade patientsMultivariate Cox modelInvasive characteristics
2023
Oncological Outcomes for Patients with European Association of Urology Very High-risk Non–muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin or Early Radical Cystectomy
Contieri R, Hensley P, Tan W, Grajales V, Bree K, Nogueras-Gonzalez G, Lee B, Navai N, Dinney C, Kamat A. Oncological Outcomes for Patients with European Association of Urology Very High-risk Non–muscle-Invasive Bladder Cancer Treated with Bacillus Calmette-Guérin or Early Radical Cystectomy. European Urology Oncology 2023, 6: 590-596. PMID: 37558542, DOI: 10.1016/j.euo.2023.07.012.Peer-Reviewed Original ResearchMeSH KeywordsAdjuvants, ImmunologicBCG VaccineCystectomyHumansNon-Muscle Invasive Bladder NeoplasmsUrinary BladderUrinary Bladder NeoplasmsUrologyConceptsNon-muscle-invasive bladder cancerCancer-specific mortalityBacillus Calmette-GuerinHigh-grade recurrenceHigh-risk non-muscle-invasive bladder cancerOverall survivalBladder cancerEuropean Urological AssociationOncological outcomesNo significant differenceEarly RCPatients treated with bacillus Calmette-GuerinTreated with bacillus Calmette-GuerinNon-muscle invasive bladder cancerIntravesical BCGContemporary cohort of patientsCancer-specific mortality ratesProgression rateBacillus Calmette-Guerin groupEarly radical cystectomyMedian follow-upInvasive bladder cancerSignificant differenceCohort of patientsEarly surgical removalImpact of age >70 years on oncological outcomes in patients with non‐muscle‐invasive bladder cancer treated with Bacillus Calmette–Guérin
Contieri R, Grajales V, Tan W, Martini A, Sood A, Hensley P, Bree K, Lobo N, Nogueras‐Gonzalez G, Guo C, Navai N, Dinney C, Kamat A. Impact of age >70 years on oncological outcomes in patients with non‐muscle‐invasive bladder cancer treated with Bacillus Calmette–Guérin. BJU International 2023, 133: 63-70. PMID: 37442564, PMCID: PMC10787034, DOI: 10.1111/bju.16127.Peer-Reviewed Original ResearchConceptsNon-muscle-invasive bladder cancerBacillus Calmette-GuerinCancer-specific mortalityCompeting-risk regression analysisCohort of patientsOncological outcomesFood and Drug AdministrationHG recurrenceAssociated with adverse oncologic outcomesHigh-gradeImpact of ageInstitutional review board-approved retrospective studyBacillus Calmette-Guerin instillationsIntravesical BCGCumulative incidence of progressionAdverse oncologic outcomesIncidence of progressionAssociation of advanced ageUnited States Food and Drug AdministrationStates Food and Drug AdministrationCumulative incidence methodPredictors of progressionStudy's primary outcomeBCG instillationRegression analysisBacillus Calmette–Guérin (BCG) unresponsive non‐muscle‐invasive bladder cancer: are the subgroups equal?
Tan W, Grajales V, Bree K, Li R, Nogueras‐Gonzalez G, Navai N, Dinney C, Kamat A. Bacillus Calmette–Guérin (BCG) unresponsive non‐muscle‐invasive bladder cancer: are the subgroups equal? BJU International 2023, 132: 384-386. PMID: 37246493, DOI: 10.1111/bju.16087.Peer-Reviewed Original Research
2022
Reply to Suman Sahoo, Abhishek Pandy, Swarnendu Mandal, Manoj Kumar Das, and Prasant Nayak’s Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non–muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003
Tan W, Mustard C, Kelly J, team H. Reply to Suman Sahoo, Abhishek Pandy, Swarnendu Mandal, Manoj Kumar Das, and Prasant Nayak’s Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non–muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003. European Urology 2022, 83: e48-e49. PMID: 36456403, DOI: 10.1016/j.eururo.2022.11.006.Peer-Reviewed Original ResearchMeSH KeywordsAdjuvants, ImmunologicAdministration, IntravesicalHumansMitomycinNon-Muscle Invasive Bladder NeoplasmsUrinary Bladder NeoplasmsReply to Fabio Campodonico, Francesca Mattioli, and Carlo Introini’s Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non–muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003
Tan W, Kelly J, team H. Reply to Fabio Campodonico, Francesca Mattioli, and Carlo Introini’s Letter to the Editor re: Wei Shen Tan, Aaron Pendergast, Charlotte Ackerman, et al. Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non–muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. Eur Urol. In press. https://doi.org/10.1016/j.eururo.2022.08.003. European Urology 2022, 83: e29-e30. PMID: 36272948, DOI: 10.1016/j.eururo.2022.10.009.Peer-Reviewed Original ResearchMeSH KeywordsAdjuvants, ImmunologicAdministration, IntravesicalHumansMitomycinNon-Muscle Invasive Bladder NeoplasmsUrinary Bladder NeoplasmsAdjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non–muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial
Tan W, Prendergast A, Ackerman C, Yogeswaran Y, Cresswell J, Mariappan P, Phull J, Hunter-Campbell P, Lazarowicz H, Mishra V, Rane A, Davies M, Warburton H, Cooke P, Mostafid H, Wilby D, Mills R, Issa R, Kelly J. Adjuvant Intravesical Chemohyperthermia Versus Passive Chemotherapy in Patients with Intermediate-risk Non–muscle-invasive Bladder Cancer (HIVEC-II): A Phase 2, Open-label, Randomised Controlled Trial. European Urology 2022, 83: 497-504. PMID: 35999119, DOI: 10.1016/j.eururo.2022.08.003.Peer-Reviewed Original ResearchConceptsIntermediate-risk non-muscle-invasive bladder cancerNon-muscle-invasive bladder cancerDisease-free survivalAdverse eventsBladder cancerMitomycin CChemotherapy instillationOpen-labelControl armAdjuvant intravesical chemotherapyProgression-free survivalPhase 2 randomised controlled trialIntention-to-treat analysisLow gradePer-protocol analysisChemohyperthermia groupIntravesical chemotherapyUrinary cytologyHeated chemotherapyOverall survivalWeekly instillationsTumor resectionPrimary endpointRandomised controlled trialsChemohyperthermiaIntermediate-risk Non–muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group
Tan W, Steinberg G, Witjes J, Li R, Shariat S, Roupret M, Babjuk M, Bivalacqua T, Psutka S, Williams S, Cookson M, Palou J, Kamat A. Intermediate-risk Non–muscle-invasive Bladder Cancer: Updated Consensus Definition and Management Recommendations from the International Bladder Cancer Group. European Urology Oncology 2022, 5: 505-516. PMID: 35718695, DOI: 10.1016/j.euo.2022.05.005.Peer-Reviewed Original ResearchMeSH KeywordsAdjuvants, ImmunologicAdministration, IntravesicalBCG VaccineConsensusHumansUrinary Bladder NeoplasmsConceptsNon-muscle-invasive bladder cancerInternational Bladder Cancer GroupBladder cancer groupManagement of patientsIntermediate-riskIntravesical treatmentCancer groupRisk factorsClinical trialsIntravesical chemotherapyMultifocal tumorsEarly recurrenceTumor sizeBladder cancerFrequent recurrenceHeterogeneous diseaseGrading systemCarcinoma in situStage of tumorPostoperative intravesical chemotherapyRandomized clinical trialsMaintenance BCGComparison of outcomesRecurrent diseaseClinical practice guidance